Auto Catch-Ups on Fidelity Drawing Board

Fidelity Investments is testing a new feature under which older participants already contributing at or close to the maximum to their 401(k) plans can "automatically" catch up.

Despite continued educational campaigns to motivate more workers to take advantage of the provision, clients were seeing a lax 9.8% take-up rate for the “catch-up” provision, which allows for employees age 50 and older to put another $5,000 a year into their 401(k) plan (in addition to the regular limit of $15,500). “That’s a number that should be dramatically higher,” James Cornell, Fidelity Senior Vice President of employer marketing said.

 Cornell said the test started about nine months ago with about 25 clients – partly at the request of activist plan sponsors who continued to struggle with how to get older participants to take advantage of the catch up provision. “These are definitely the more aggressive clients we’ve got,” Cornell told PLANADVISER.com.

 He said the “auto catch-up” program was being implemented differently by different clients, including a difference in how quickly participants were to be increased to the legal ceiling.

 The initial effort is largely focused on highly compensated employees (HCE) already contributing at or close to the legal limit. “We want to move the needle (on the take-up rate) for all participants, not just HCEs,” Cornell said. “But they may be the first beneficiaries of this.”

 Cornell said Fidelity intends to keep the test going until the spring and then meet with clients to decide how to proceed from there. The company would like to eventually roll out the “auto catch-up” provision to all its 401(k) clients, he said. Clients were reporting strong acceptance of the move by participants with few opting out. “It’s a very, very powerful mover of participant behavior,” according to Cornell.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For more stories like this, sign up for the PLANADVISERdash daily newsletter.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NY Firm Unveils ETFs for Health, Biotech Research

New York-based XShares Advisors LLC launched five exchange-traded funds (ETFs) on the New York Stock Exchange Tuesday, with each aimed at a segment of the health care, life science and biotechnology industries.

XShares said the new ETFs take a “vertical” approach to sector investing and that they will allow customers to emphasize in their investments diagnosing or treatment of diseases such as heart disease or cancer, according to a Reuters news report. Each will track an index of 22 to 25 stocks.

For more stories like this, sign up for the PLANADVISERdash daily newsletter.

According to the news report, the new ETFs are:

  • the Healthcare Cardio Devices Exchange Traded Fund.

  • the Diagnostics ETF.

  • the Emerging Cancer ETF.

  • the Enabling Technologies ETF; and

  • the Patient Care Services ETF.

Reuters said the Enabling Technologies ETF takes positions in companies that provide products or services that support the discovery, development and manufacturing efforts of pharmaceutical and biotechnology firms.

Bill Kridel, chairman, chief executive and co-founder of XShares, told Reuters that the approach allows investors to make precise investments within health care that would be narrower than what is found in a traditional health care mutual fund.

The annual expense-ratio for the five new ETFs is being capped at 0.75%, according to the news report.

«